The most important change for the US Medical Meeting Industry is that MedTech Europe member companies will not be able to directly sponsor an HCP, neither as a delegate nor as a speaker. As of 2018, MedTech Europe will require all meetings to be vetted through its Conference Vetting System, only these meetings will be eligible to receive funds from MedTech Europe member companies, — and only through educational grants.
Healthcare Organizations should brace themselves for an impact and will need to plan for a loss in revenue from any international delegation sponsored by Medical Technology Companies in Europe. From the ABTS portfolio of clients, we expect about 30 percent of delegations to be at risk for 2018 unless there is an overhaul of the current process to meet the Common Code requirements.